Ketogenic conditions during Radiotherapy
Author: Sture Hobro
Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung and Pancreatic Cancer: The University of Iowa Experience of Two Phase I Clinical Trials - PMC (nih.gov)
This study Concludes: “Overall, the current study continues to support the hypothesis that ketogenic diets are capable of increasing tumor responses to radiation in rodent xenograft models. Our studies in humans also continue to demonstrate the difficulty for adults to comply with a ketogenic diet while receiving concurrent radiation and chemotherapy in locally advanced NSCLC and pancreatic cancer.“
Figure 3 A and B in this article shows how extraordinarily bad both ketogenic diet or radiation treatment work as single treatments on this more or less treatment-resistant cancer in a mice model. This in sharp contrast to how extraordinarily well the combination of both KD and radio works. If you read our article about #CancerDialysis, you can see how “symbiotic” radiation (and most chemo therapies) work with ketogenic conditions. Radiation works by increasing oxidative stress in cancer cells, and ketogenic conditions remove cancer cells’ ability to handle oxidative stress. Radiation is king, and the ketogenic condition is queen, and together they form a ruling kingdom.
The ketogenic condition is not that easy to achieve, and a medical ketogenic diet is a problematic diet that requires much from the patient and is proven to be hard to follow.
#CancerDialysis does not require a long-term diet, to suddenly, within minutes create pronounced ketogenic conditions in the patient. The question to answer with coming clinical studies is how effective such a radiation and ketogenic blow will be to cancer cells.
Important to note is that dialysis without glucose in kidney patients is proven to be safe and effective in lowering blood glucose. Therefore, a new CancerDialysis treatment may be rather easy compared to many other cancer therapies to bring out to help cancer patients facing treatment resistant cancer.
As is, our company has decided as a non-cancer company that we must have a partner to bring this treatment out to the market and we are still working to set up a joint venture to explore this new treatment opportunity. Contact us if you want to learn more.
